2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-124947
    PF-4522654 1065109-28-5 98%
    PF-4522654 is a potent, selective and brain-permeable 5-HT2C receptor agonist with an EC50 of 16 nM and a Ki of 8 nM. PF-4522654 shows no measurable functional agonism at no 5-HT2A and 5-HT2B receptors. PF-4522654 can be used for the study of stress urinary incontinence (SUI).
    PF-4522654
  • HY-124954
    MN-25 501926-82-5 98%
    MN-25 (compound 4a) is an orally active indolpyridone that serves as a novel cannabinoid ligand. MN-25 has Ki of 245 nM and 11 nM for CB1 and CB2. MN-25 has CB2 agonist activity and inhibits TNF-R release in human peripheral blood mononuclear cells in vitro with an IC50 of 33 μM. MN-25 shows efficacy in a mouse acute inflammation model at oral doses up to 50 mg/kg>[1].
    MN-25
  • HY-124985
    VU6010608 2165325-42-6 98%
    VU6010608 is a blood-brain barrier-crossing mGlu7 negative allosteric modulator (IC50 = 0.76 μM). VU6010608 can block long-term enhancement (LTP) of SC-CA1 synapses in mouse brain slices induced by high-frequency stimulation. VU6010608 can be used for research on neurological diseases.
    VU6010608
  • HY-125047
    Daledalin tosylate 23226-37-1 98%
    Daledalin tosylate is an orally active indoline antidepressant targeting noradrenaline and serotonin transporters in the brain. Daledalin tosylate enhances central monoaminergic neurotransmission to alleviate depressive symptoms. Daledalin tosylate is proming for rasearch of depression, including endogenous and neurotic depression.
    Daledalin tosylate
  • HY-125194
    NWL-117 2267318-43-2 98%
    NWL-117 is a brain-penetrant and highly selective Caspase-6 (Casp6) inhibitor with an IC50 value of 192 nM. NWL-117 is promising for research of neurodegenerative diseases, particularly Alzheimer's disease and Huntington's disease .
    NWL-117
  • HY-12520B
    (R)-SKF 38393 hydrochloride 81702-42-3 98%
    (R)-SKF 38393 ((±)-SKF-38393) hydrochloride is a potent and selective D1 dopamine receptor antagonist. (R)-SKF 38393 hydrochloride inhibits G protein-coupled inwardly rectifying potassium (GIRK) channel.
    (R)-SKF 38393 hydrochloride
  • HY-125251
    D159153 1158231-00-5 98%
    D159153 is a highly selective phosphodiesterase 4 (PDE4) inhibitor. D159153 is promising for research of asthma, chronic obstructive pulmonary disease (COPD), and neuroinflammatory disorders.
    D159153
  • HY-125404
    DAPK-IN-1 313971-05-0 98%
    DAPK-IN-1 (The fifth compound in page 19) is a DAPK1 and DAPK3 inhibitor. DAPK-IN-1 is applicable to research related to cerebral infarction, myocardial infarction and renal failure.
    DAPK-IN-1
  • HY-125405
    AZ3971 1260248-03-0 98%
    AZ3971 is an orally active, blood-brain barrier permeable BACE1 inhibitor that does not affect the activity of γ-secretase. AZ3971 reduces the production of Aβ. AZ3971 can be used for the research of Alzheimer's disease.
    AZ3971
  • HY-12542R
    Dantrolene (Standard) 7261-97-4
    Dantrolene (Standard) is the analytical standard of Dantrolene. This product is intended for research and analytical applications. Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene is a direct-acting skeletal muscle relaxant. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.
    Dantrolene (Standard)
  • HY-12542S
    Dantrolene-13C3 1185234-99-4 99.0%
    Dantrolene-13C3 is the 13C3 labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.
    Dantrolene-13C3
  • HY-125431
    LY 202769 139543-40-1 98%
    LY 202769 (Example 26) is a cholecystokinin (CCK) and gastrin receptor (gastrin receptor) antagonist. LY 202769 is applicable for the research of gastrointestinal diseases and central nervous system diseases.
    LY 202769
  • HY-125500
    TOP1362 1630203-25-6 98%
    TOP1362 is a narrow spectrum kinase inhibitor. TOP1362 is a potent inhibitor of P38-α and Syk kinases with Kd values of 26 and 18 nM, respectively and an IC50 of 14 nM in the Src kinase activity assay. TOP1362 potently inhibits P38-α, Src and Syk. TOP1362 can be used in the research of dry eye syndrome.
    TOP1362
  • HY-125547
    EIDD-1723 1659302-89-2 98%
    EIDD-1723 is a Progesterone (HY-N0437) analogues, that binds progesterone receptor (PR) with an IC50 of 2.25 μM. EIDD-1723 is the prodrug of EIDD-036 (HY-17649). EIDD-1723 may exert its neuroprotective effects not solely through progesterone receptor (PR)-dependent pathways but also via non-genomic mechanisms, such as modulation of inflammatory responses and oxidative stress. EIDD-1723 can be used for the study of traumatic brain injury (TBI).
    EIDD-1723
  • HY-125555
    Azosulfamide 133-60-8 98%
    Azosulfamide has an anticonvulsant effect and can be used for research of epilepsy. Azosulfamide is active against recurrent tetanus.
    Azosulfamide
  • HY-125627
    CP-394531 305822-63-3 98%
    CP-394531 is an efficient and highly selective non-steroidal glucocorticoid receptor (GR) antagonist, with a Ki value of 0.1 nM. CP-394531 has a weak binding to androgen receptor (AR) (Ki = 130 nM), and has almost no effect on progesterone receptor (PR) and estrogen receptors (ERα, ERβ). CP-394531 completely blocks the half-maximal agonistic effect induced by Dexamethasone (HY-14648G), with a Kif of 4.1 nM. CP-394531 can be used to study various diseases such as diabetes, obesity, depression, neurodegenerative diseases, glaucoma and Cushing's disease.
    CP-394531
  • HY-125673
    AC-178335 212966-15-9 98%
    AC-178335 is a SRIF antagonist, with a Ki of 172 nM. AC-178335 blocks SRIF inhibition of adenylate cyclase in vitro (IC50=5.1 μM). AC-178335 induces GH release in anesthetized rats.
    AC-178335
  • HY-125692
    L-740093 154967-59-6 98%
    L-740093 is a potent cholecystokinin-B receptor antagonist. L-740093 has excellent central nervous system (CNS) penetration.
    L-740093
  • HY-125693
    L685818 143839-74-1 98%
    L685818 is a specific immunophilin ligand. L685818 was neuroregenerative and non-neuroprotective in primary brain cultures. L685818 protects dopaminergic neurons from toxic inhibition of MPP+ and 6-OHDA, reduces tyrosine hydroxylase (TH) loss, and promotes neuronal process regeneration. L685818 is also an antifungal reagent for Cryptococcus neoformans.
    L685818
  • HY-125714
    Isoapoptolidin 476647-30-0 98%
    Isoapoptolidin is a mitochondrial F0F1-ATPase inhibitor (Ki>100 μM, selective for mitochondrial complex V). Isoapoptolidin is promising for research of mitochondrial energy metabolism-related diseases (e.g., cancer, neurodegeneration).
    Isoapoptolidin
Cat. No. Product Name / Synonyms Application Reactivity